STOCK TITAN
  1. Home
  2. Sec-filings
  3. LLY
  4. [Form 4] Eli Lilly & Co. Insider Trading Activity

Eli Lilly Insider Purchase: Jacob Van Naarden Acquires 1,000 LLY Shares

Filing Impact
(Very High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Jacob Van Naarden, EVP & President, Lilly Oncology, reported an acquisition of 1,000 shares of Eli Lilly & Co. (LLY) on 08/13/2025 at a reported price of $647.36 per share. The Form 4 shows the reporting person’s direct beneficial ownership following the transaction as 20,561.985 shares.

The filing also lists indirect holdings of 4,342 shares held by the Van Naarden Family Trust and 4,302 shares held by the reporting person’s spouse. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form is signed by Jonathan Groff on behalf of Jacob Van Naarden, dated 08/13/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Officer reported a small purchase of 1,000 LLY shares on 08/13/2025; filing lists direct and indirect holdings.

The Form 4 documents a purchase transaction of 1,000 LLY shares at $647.36 per share by Jacob Van Naarden, an executive officer. The filing quantifies direct ownership at 20,561.985 shares and specifies two indirect holdings of 4,342 and 4,302 shares respectively. From a market-materiality perspective, the form is a routine Section 16 disclosure providing transparency on insider ownership and cash purchases; it contains no additional derivative activity or other compensatory transactions.

TL;DR: Standard Form 4 insider purchase filed by an officer; includes disclaimer and trust/spouse indirect holdings.

The filing conforms to Section 16 reporting: it identifies the reporting person as an officer (EVP & Pres., Lilly Oncology), records an open-market purchase of 1,000 shares, and discloses indirect ownership via a family trust and spouse. The report includes a pecuniary-interest disclaimer and is signed pursuant to authorization, indicating proper procedural completion. No amendments, derivative transactions, or departures from standard disclosure practice are present in this filing.

Insider Van Naarden Jacob
Role EVP & Pres., Lilly Oncology
Bought 1,000 shs ($647K)
Type Security Shares Price Value
Purchase Common Stock 1,000 $647.36 $647K
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 20,561.985 shares (Direct); Common Stock — 4,342 shares (Indirect, Van Naarden Family Trust)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Van Naarden Jacob
(Last) (First) (Middle)
LILLY CORPORATE CENTER
(Street)
INDIANAPOLIS IN 46285
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Pres., Lilly Oncology
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/13/2025 P 1,000 A $647.36 20,561.985 D
Common Stock 4,342 I Van Naarden Family Trust(1)
Common Stock 4,302 I By spouse(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Remarks:
/s/ Jonathan Groff for Jacob Van Naarden, pursuant to authorization on file 08/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What transaction did Jacob Van Naarden report on Form 4 for LLY?

The Form 4 reports the purchase of 1,000 shares of Eli Lilly & Co. (LLY) on 08/13/2025 at $647.36 per share.

What is Jacob Van Naarden's role at Eli Lilly as listed on the filing?

The filing lists Jacob Van Naarden as EVP & President, Lilly Oncology.

How many LLY shares does the Form 4 show Van Naarden directly owns after the transaction?

The Form 4 reports 20,561.985 shares as the amount of securities beneficially owned directly following the reported transaction.

Does the filing disclose any indirect holdings for Van Naarden?

Yes. The filing discloses indirect holdings of 4,342 shares in the Van Naarden Family Trust and 4,302 shares held by the reporting person’s spouse.

Who signed the Form 4 and when?

The Form 4 is signed by /s/ Jonathan Groff on behalf of Jacob Van Naarden, dated 08/13/2025.